Evidence map›Paper›PMID 40703477›Full record

ArticleFarmaceuticos comunitarios2025

[Phenotypic Classification of Diabetes: A Personalized Approach for Pharmaceutical Practice].

J García Soláns

Abstract readEnglish Abstract
In one paragraph

Article in Farmaceuticos comunitarios, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

J García SolánsFarmacéutico comunitario. Zaragoza España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Diabetes mellitus (DM) is a heterogeneous metabolic disease with multiple pathophysiological mechanisms. The traditional classification into type 1 diabetes (T1D) and type 2 diabetes (T2D) does not fully capture the diversity of clinical and metabolic profiles among patients. Recently, Ahlqvist et al. proposed a model based on five phenotypic subtypes, enabling a more precise stratification of the disease and a personalized therapeutic approach. Methods: Through cluster analysis in cohorts of diabetic patients, five subgroups were identified: Severe Autoimmune Diabetes (SAID), Severe Insulin Deficient Diabetes (SIDD), Severe Insulin Resistant Diabetes (SIRD), Mild Obesity-related Diabetes (MOD), and Mild Age-related Diabetes (MARD). These phenotypes differ in pathophysiology, disease progression, and treatment response. Results and Discussion: Phenotypic stratification allows better prediction of microvascular and macrovascular complications, optimizes pharmacotherapy, and enhances personalized interventions. In community pharmacy, this classification could improve subtype identification, facilitate more precise therapeutic recommendations, and promote treatment adherence. However, its implementation faces challenges, such as limited access to key biomarkers. Conclusions: The phenotypic classification of DM represents a step toward personalized medicine. As key healthcare professionals in chronic disease management, community pharmacists can play a crucial role in its application, improving patient education and therapeutic monitoring to enhance clinical outcomes.

Indexed as

Diabetes MellitusPrecision MedicineDiabetes Mellitus, Type 2HumansPhenotypeDiabetes Mellitus/classificationPharmaceutical ServicesPrecision Medicine

Identifiers

PMID40703477
PMCPMC12282472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.